Basic Information
| LncRNA/CircRNA Name | LINC00339 |
| Synonyms | NA |
| Region | NA |
| Ensemble | ENSG00000218510 |
| Refseq | NR_023918 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Luciferase reporter assay, in vitro knockdown |
| Sample | HCC cell lines (HepG2, Hep3B, SMMC-7721, Huh7, and MHCC97H) and the normal hepatocyte cell line (LO2), HCC tissues |
| Expression Pattern | up-regulated |
| Function Description | LINC00339 overexpression was correlated with an advanced stage, metastasis, and bad prognosis in HCC patients. Functional investigation showed that LINC00339 knockdown significantly suppressed HCC cell proliferation, migration, and invasion. Moreover, decreased LINC00339 expression inhibited HCC growth in vivo. Mechanistically, LINC00339 could interact with miR-1182 to promote SKA1 expression. We also demonstrated that SKA1 acted as an oncogene and SKA1 upregulation reversed the effect of LINC00339 silencing |
| Pubmed ID | 31239716 |
| Year | 2019 |
| Title | LINC00339 promotes growth and invasiveness of hepatocellular carcinoma by the miR-1182/SKA1 pathway |
External Links
| Links for LINC00339 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |